CONSOLIDATED STATEMENTS OF CASH FLOWS | |||||||||
(Unaudited) | |||||||||
|
Three Months Ended |
|
Year Ended | ||||||
|
June 28, |
|
March 29, |
|
June 29, |
|
June 28, |
|
June 29, |
|
2014 |
|
2014 |
|
2013 |
|
2014 |
|
2013 |
|
(in thousands) | ||||||||
Cash flows from operating activities: |
|
|
|
|
|
|
|
|
|
Net income |
$ 84,793 |
|
$ 122,544 |
|
$ 119,014 |
|
$ 354,810 |
|
$ 454,912 |
Adjustments to reconcile net income to net cash provided by operating activities: |
|
|
|
|
|
|
|
|
|
Stock-based compensation |
21,786 |
|
22,057 |
|
18,853 |
|
85,452 |
|
83,808 |
Depreciation and amortization |
64,391 |
|
64,665 |
|
51,191 |
|
244,593 |
|
207,136 |
Deferred taxes |
(9,501) |
|
(36,482) |
|
(2,813) |
|
(32,159) |
|
25,372 |
Loss (gain) from sale of property, plant and equipment |
1,068 |
|
818 |
|
1,380 |
|
2,187 |
|
(1,156) |
Tax benefit (shortfall) related to stock-based compensation |
942 |
|
3,204 |
|
358 |
|
(68) |
|
8,197 |
Impairment of long-lived assets |
6,447 |
|
- |
|
- |
|
11,644 |
|
24,929 |
Impairment of investments in privately-held companies |
6,537 |
|
3,723 |
|
700 |
|
10,260 |
|
700 |
In-process research and development written-off |
- |
|
2,580 |
|
- |
|
2,580 |
|
2,800 |
Loss (gain) on sale of discontinued operations |
- |
|
- |
|
- |
|
- |
|
(3,285) |
Excess tax benefit from stock-based compensation |
(4,897) |
|
(5,139) |
|
(2,792) |
|
(14,192) |
|
(18,923) |
Changes in assets and liabilities: |
|
|
|
|
|
|
|
|
|
Accounts receivable |
8,300 |
|
(15,566) |
|
14,608 |
|
13,340 |
|
32,023 |
Inventories |
1,226 |
|
7,717 |
|
(7,657) |
|
20,672 |
|
(35,245) |
Other current assets |
26,579 |
|
7,194 |
|
(2,832) |
|
45,557 |
|
(21,233) |
Accounts payable |
5,203 |
|
(4,044) |
|
(6,961) |
|
(11,255) |
|
(32,510) |
Income taxes payable |
9,853 |
|
14,244 |
|
13,118 |
|
54,492 |
|
70,156 |
Deferred revenue on shipments to distributors |
1,475 |
|
(1,283) |
|
706 |
|
(823) |
|
277 |
All other accrued liabilities |
9,882 |
|
25,466 |
|
17,527 |
|
(10,983) |
|
19,977 |
Net cash provided by (used in) operating activities |
234,084 |
|
211,698 |
|
214,400 |
|
776,107 |
|
817,935 |
|
|
|
|
|
|
|
|
|
|
Cash flows from investing activities: |
|
|
|
|
|
|
|
|
|
Purchase of property, plant and equipment |
(23,654) |
|
(26,407) |
|
(48,922) |
|
(132,523) |
|
(216,672) |
Proceeds from sales of property, plant and equipment |
1,627 |
|
618 |
|
4,538 |
|
5,293 |
|
19,196 |
Proceeds from sales of property, plant and equipment through note receivable |
- |
|
- |
|
10,786 |
|
- |
|
10,786 |
Proceeds from maturity of available-for-sale securities |
- |
|
- |
|
- |
|
27,000 |
|
50,000 |
Purchases of available-for-sale securities |
(49,953) |
|
- |
|
- |
|
(49,953) |
|
- |
Purchases of privately-held companies securities |
- |
|
- |
|
(500) |
|
- |
|
(500) |
Payments in connection to acquisitions |
- |
|
(5,750) |
|
(2,767) |
|
(459,256) |
|
(2,767) |
Proceeds from sale of investments in privately-held companies |
- |
|
- |
|
585 |
|
- |
|
585 |
Net cash provided by (used in) investing activities |
(71,980) |
|
(31,539) |
|
(36,280) |
|
(609,439) |
|
(139,372) |
|
|
|
|
|
|
|
|
|
|
Cash flows from financing activities: |
|
|
|
|
|
|
|
|
|
Excess tax benefit from stock-based compensation |
4,897 |
|
5,139 |
|
2,792 |
|
14,192 |
|
18,923 |
Contingent consideration paid |
- |
|
(104) |
|
(6,305) |
|
(4,705) |
|
(13,781) |
Dividends paid |
(73,626) |
|
(73,481) |
|
(69,532) |
|
(294,175) |
|
(280,215) |
Repayment of notes payable |
(2,430) |
|
(439) |
|
(302,299) |
|
(4,708) |
|
(303,500) |
Issuance of debt |
- |
|
- |
|
- |
|
497,895 |
|
494,395 |
Debt issuance cost |
- |
|
- |
|
(671) |
|
(3,431) |
|
(3,921) |
Repurchase of common stock |
(40,744) |
|
(51,083) |
|
(193,221) |
|
(305,314) |
|
(375,135) |
Issuance of ESPP shares under employee stock purchase program |
23,713 |
|
- |
|
19,529 |
|
42,809 |
|
36,297 |
Net issuance of restricted stock units |
(8,922) |
|
(8,390) |
|
(7,456) |
|
(31,384) |
|
(29,042) |
Proceeds from stock options exercised |
26,232 |
|
29,538 |
|
6,049 |
|
69,639 |
|
71,342 |
Net cash provided by (used in) financing activities |
(70,880) |
|
(98,820) |
|
(551,114) |
|
(19,182) |
|
(384,637) |
|
|
|
|
|
|
|
|
|
|
Net increase (decrease) in cash and cash equivalents |
91,224 |
|
81,339 |
|
(372,994) |
|
147,486 |
|
293,926 |
Cash and cash equivalents: |
|
|
|
|
|
|
|
|
|
Beginning of period |
1,231,248 |
|
1,149,909 |
|
1,547,980 |
|
1,174,986 |
|
881,060 |
End of period |
$1,322,472 |
|
$1,231,248 |
|
$1,174,986 |
|
$1,322,472 |
|
$1,174,986 |
|
|
|
|
|
|
|
|
|
|
Total cash, cash equivalents and short-term investments |
$1,372,425 |
|
$1,231,248 |
|
$1,200,046 |
|
$1,372,425 |
|
$1,200,046 |
|
|
|
|
|
|
|
|
|
|
Maxim Integrated Reports Results For The Fourth Quarter Of Fiscal 2014; Increases Dividend By 8%
| | More IC News |
|
RELATED NEWS